Ibrutinib-associated pityriasis rosea–like rash

Bitar, Carole; Sadeghian, Azeen; Sullivan, Lacey; Murina, Andrea

doi:10.1016/j.jdcr.2017.06.035

Cited by 20 publications

(15 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 4 When the skin rash is diagnosed as a drug reaction with morphological features similar to genuine PR (a PR-like eruption), it is preferable to stop the drug immediately to prevent more dangerous drug reactions. Indeed, the interesting case described by Bitar et al 1 has some of the characteristics of PR-like eruptions such as the presence of itch on the lesions, the dusky-red color of the lesions, and the superficial and perivascular eosinophil infiltration in the dermis. However, it is uncommon after several months to have resolution of the eruption without interruption of the drug.…”

mentioning

confidence: 98%

See 1 more Smart Citation

Pityriasis rosea and pityriasis rosea-like eruptions: How to distinguish them?

2018

View full text Add to dashboard Cite

mentioning

confidence: 98%

“…To the Editor : We appreciate the article from Bitar et al 1 on ibrutinib-associated pityriasis rosea (PR)-like rash that allows us to share our experience and make some observations. Recently, we proposed criteria to distinguish PR from PR-like eruptions ( Table I ).…”

mentioning

confidence: 99%

Pityriasis rosea and pityriasis rosea-like eruptions: How to distinguish them?

2018

View full text Add to dashboard Cite

“…1-3 Several cases have reported variable skin toxicities to ibrutinib therapy in CLL; MCL and WM patients. 4,12,13 A thorough database search to review the literature for any evidence regarding ibrutinib-associated dermatological adverse events was performed. In early phase clinical trials, ibrutinib was tested as monotherapy in MCL, CLL and small lymphocytic leukemia (SLL), and it was associated with a frequency of 13-27% of rash occurrence.…”

Section: Discussionmentioning

confidence: 99%

Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia – Case report and literature review

Ghasoub

AlBattah

Elazzazy

et al. 2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Ibrutinib is an oral inhibitor of Bruton’s tyrosine kinase that is used for a variety of B cell hematological malignancies. Skin and subcutaneous tissue manifestations have been reported and were witnessed in up to 32% of the patients on ibrutinib. The mechanism in which ibrutinib can cause skin toxicities has been thought due to the inhibition of epidermal growth factor; c-Kit and platelet-derived growth factor receptor). Here, we report a case of an elderly chronic lymphocytic leukemia patient who developed multiple inflamed lesions and lower limb cellulitis in 100 days after initiating ibrutinib therapy. Case report A 68-year-old male patient with relapsed chronic lymphocytic leukemia was started on ibrutinib 420 mg orally daily following multiple lines of therapy. Three months following ibrutinib, the patient developed multiple hyper pigmented lesions over both forearms then over both thighs; buttocks and lower limbs. The lesions were labeled as ecthyma and cellulitis that started as papules, which progressed to pustules. Management and outcomes The patient required admission in which he received prolonged course of antibiotics. Biopsy from the wound showed soft tissue fragment infiltrated by acute and chronic inflammatory cells with necrosis; rare foreign body giant cells and granulation tissue formation; suggestive of abscess. Subsequently, ibrutinib was stopped permanently. Discussion This is the first case description of an ibrutinib-associated sever skin toxicity in Qatar. The provided information regarding the clinical descriptions of toxicity profiles in general and skin-based in particular is valuable information for daily clinical practice, especially when selecting the optimum first-line treatment for the patient.

show abstract

“…To the Editor : We appreciate the opportunity to respond to the letter by Drago et al, regarding our recently published report, “Ibrutinib-associated pityriasis rosea-like rash.” 1 …”

mentioning

confidence: 99%

“…We did not advocate for discontinuation of the medication because the patient's chronic lymphocytic leukemia was responsive to ibrutinib. 1 The risk of discontinuing ibrutinib outweighed the benefit. We appreciate the comparison table that outlines the clinical, histopathologic, and virologic criteria, which can serve as a guide when evaluating patients for suspected PR or PR-like eruptions caused by a drug.…”

Ibrutinib-associated pityriasis rosea–like rash

Cited by 20 publications

References 12 publications

Pityriasis rosea and pityriasis rosea-like eruptions: How to distinguish them?

Pityriasis rosea and pityriasis rosea-like eruptions: How to distinguish them?

Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia – Case report and literature review

Reply: Commentary on letter to the editor from Drago et al

Contact Info

Product

Resources

About